IGC Pharma (IGC) said Tuesday it is expanding its phase 2 trial of IGC-AD1 in Alzheimer's disease by adding Butler Hospital's Memory and Aging Program in Providence, Rhode Island.
The site will help enroll participants for the study of IGC-AD1
potential in reducing agitation in Alzheimer's dementia, the company said. The research center is affiliated with the Warren Alpert Medical School of Brown University.
The trial is being conducted in the US and Canada, with a goal of enrolling 146 participants, IGC said.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。